Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...

Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...

Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...

(ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor ...

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate ...

The company is building a new facility in California, its third U.S.-based radioligand therapy production site, and expanding ...

Novartis (NVS) expands radioligand therapy production in the U.S. with two new manufacturing sites in Indianapolis and ...

Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...